Business Context and Reporting Period
This Form 8-K was filed by Medasorb Technologies Corporation (referred to in metadata as Cytosorbents Corp) on April 9, 2010. The report details significant changes to the company's executive leadership and the renewal of a key consulting agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The financial data presented is limited to the compensation terms of new executive employment agreements:
- David Lamadrid (CFO): $175,000 annual base salary.
- Vince Capponi (COO): $205,303 annual base salary.
- Philip P. Chan (CEO/President): $216,351 annual base salary.
Material Changes
The primary material change reported is the appointment of three new officers effective retroactively to January 1, 2010, and the renewal of a consulting agreement:
- Executive Appointments: David Lamadrid appointed as CFO; Vince Capponi appointed as COO; Philip P. Chan appointed as CEO and President.
- Consulting Renewal: Dr. Robert Bartlett's consulting agreement as Chief Medical Officer (CMO) was renewed through December 31, 2010.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of market risks. However, it outlines specific contractual contingencies regarding the new employment agreements:
- Termination Clauses: Employment may be terminated with 15 days' notice for "justifiable cause." The company reserves the right to suspend employees without compensation pending legal adjudication of certain actions.
- Disability: Termination is permitted in the event of permanent disability, with benefits activating 90 days post-termination.
- Non-Compete: Employees are prohibited from engaging in competing businesses within the United States and specified foreign areas for one year following separation.
Investor Verification Checklist
- Verify the retroactive effective date of January 1, 2010, for the new executive appointments.
- Confirm the total annual compensation liability of approximately $596,654 for the three new officers.
- Review the specific definitions of "justifiable cause" in the attached employment agreements (Exhibits 10.1, 10.2, and 10.3).
- Check if Dr. Robert Bartlett has been appointed to any board committees, as the filing states he has not as of the report date.